Does B18.1 require prior authorization?

No, B18.1 does not require prior authorization (medium confidence). Covered without prior authorization by at least one policy, though another does not cover it.

Backwork Sign up free

`B18.1`, Chronic viral hepatitis B without delta-agent

ICD-10-CM

Prior Authorization

No Prior Auth Required

Covered without prior authorization by at least one policy, though another does not cover it (medium confidence)

Documentation Required

This billing and coding article provides guidelines that complement Local Coverage Determination L34415 for CT of the abdomen and pelvis; consult LCD L34415 for specific coverage indications, limitations, and documentation requirements.
Medical records must document the indication(s) supporting use of IVIG for each claim.
For indications where routine IVIG use is not indicated, the medical record must document prior interventions that were unsuccessful or reasons those interventions were not tolerated.

Key Coverage Criteria

IVIG is covered only for indications specified as covered in the related Local Coverage Determination (LCD) and when medical necessity criteria in that LCD are met.
Pharmacogenomics (PGx) testing is covered when it is reasonable and necessary per LCD L39063 and Medicare coverage rules for the beneficiary's clinical indication.
CPT 81418 (PGx multi-gene panel) is covered when the test assays at least 6 genes, including CYP2C19 and CYP2D6 and CYP2D6 duplication/deletion analysis, and the panel is clinically indicated to guide drug therapy.
A clinician-ordered single gene or allele test is considered covered when the billed component corresponds to the single gene/allele that was reasonable and necessary, even if the laboratory platform concurrently interrogated other genes operationally.
Germline testing panels that include some previously tested genetic content may be covered if there is established clinical utility for the remaining non-duplicative genetic components of the panel.
Genes may be assayed serially or in parallel; additional gene analyses done after a reflex decision are covered when those reflexive analyses are reasonable and necessary for the beneficiary's care.

20 Active Policies

WPS-J5-L34771, Immune Globulins

A57554, Billing and Coding: Immune Globulins

A59915, Billing and Coding: Pharmacogenomic Testing

NGS-J6-L39995, Pharmacogenomic Testing

WPS-J8-L34771, Immune Globulins

FIRST_COAST-L39073, Pharmacogenomics Testing

A58812, Billing and Coding: Pharmacogenomics Testing

NOVITAS-JH-L39063, Pharmacogenomics Testing

NGS-JK-L39995, Pharmacogenomic Testing

A58801, Billing and Coding: Pharmacogenomics Testing

NOVITAS-JL-L39063, Pharmacogenomics Testing

AETNA-CPB-0544, Immune Globulins for Post-Exposure Prophylaxis

AETNA-CPB-0135, Acupuncture and Dry Needling

AETNA-CPB-0355, Extracorporeal Immunoadsorption (Prosorba Column)

ANTHEM-LAB.00019, Proprietary Algorithms for Liver Fibrosis

AETNA-CPB-0605, Intestinal Transplantation

AETNA-CPB-0650, Polymerase Chain Reaction Testing: Selected Indications

AETNA-CPB-0690, Noninvasive Tests for Hepatic Fibrosis

AETNA-CPB-0780, ADAMTS13 Assay for Thrombotic Thrombocytopenic Purpura (TTP)

A56421, Billing and Coding: CT of the Abdomen and Pelvis

`B18.1`, Chronic viral hepatitis B without delta-agent

Prior Authorization

Documentation Required

Key Coverage Criteria

20 Active Policies

Related Codes

Have a follow-up question?

B18.1, Chronic viral hepatitis B without delta-agent

Prior Authorization

Documentation Required

Key Coverage Criteria

20 Active Policies

Related Codes

Have a follow-up question?

`B18.1`, Chronic viral hepatitis B without delta-agent